Correlation Between Ultragenyx and Arrowhead Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ultragenyx and Arrowhead Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ultragenyx and Arrowhead Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ultragenyx and Arrowhead Pharmaceuticals, you can compare the effects of market volatilities on Ultragenyx and Arrowhead Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ultragenyx with a short position of Arrowhead Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ultragenyx and Arrowhead Pharmaceuticals.

Diversification Opportunities for Ultragenyx and Arrowhead Pharmaceuticals

0.38
  Correlation Coefficient

Weak diversification

The 3 months correlation between Ultragenyx and Arrowhead is 0.38. Overlapping area represents the amount of risk that can be diversified away by holding Ultragenyx and Arrowhead Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Arrowhead Pharmaceuticals and Ultragenyx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ultragenyx are associated (or correlated) with Arrowhead Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Arrowhead Pharmaceuticals has no effect on the direction of Ultragenyx i.e., Ultragenyx and Arrowhead Pharmaceuticals go up and down completely randomly.

Pair Corralation between Ultragenyx and Arrowhead Pharmaceuticals

Given the investment horizon of 90 days Ultragenyx is expected to under-perform the Arrowhead Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Ultragenyx is 1.41 times less risky than Arrowhead Pharmaceuticals. The stock trades about -0.22 of its potential returns per unit of risk. The Arrowhead Pharmaceuticals is currently generating about -0.08 of returns per unit of risk over similar time horizon. If you would invest  2,018  in Arrowhead Pharmaceuticals on August 27, 2024 and sell it today you would lose (139.00) from holding Arrowhead Pharmaceuticals or give up 6.89% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Ultragenyx  vs.  Arrowhead Pharmaceuticals

 Performance 
       Timeline  
Ultragenyx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Arrowhead Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Arrowhead Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Ultragenyx and Arrowhead Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ultragenyx and Arrowhead Pharmaceuticals

The main advantage of trading using opposite Ultragenyx and Arrowhead Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ultragenyx position performs unexpectedly, Arrowhead Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will offset losses from the drop in Arrowhead Pharmaceuticals' long position.
The idea behind Ultragenyx and Arrowhead Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk